Now Up Approx. 12%, Nasdaq Profile (NTRB) Maintains Green Surge On Breaking News

NTRB is not showing any signs of slowing down. Now Up Approx. 12%, Nasdaq Profile (NTRB) Maintains Green Surge On Breaking News July 27th Dear Reader, NTRB is not showing any signs of slowing down. After hitting an early high of $4.88, NTRB is now up approximately 12%. This comes after the company's major announcement: [Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings]( Don't forget. NTRB has a [low float]( of fewer than 5Mn shares along with several triggered technicals over at [Barchart.]( On top of that, a $10 [Zacks SCR]( target continues to suggest over 100+% potential upside from current levels. Make sure to get NTRB on your radar before it's too late. ----- Attention needs to now shift to a fresh Nasdaq breakout idea, ready for Thursday's opening bell. It's essential to be vigilant about potential volatility with this profile, given that it involves a low float. Yahoo Finance has reported the float to be below 5Mn shares, indicating that volatility could skyrocket quickly and with little to no notice. Additionally, at the time of writing, [Barchart]( was indicating that this profile had at least 8 triggered technical indicators. The significance lies in the fact that this number of activated technicals is substantially higher compared to the same point last week. Now, factor in some compelling patent-related news and a recent revenue growth announcement... ... and this Nasdaq profile might become highly explosive, waiting for a spark to ignite it. With an [analyst target]( proposing a potential upside of over 100+% from today's closing valuation, it's imperative to get this profile on your radar now: *Nutriband Inc. (NTRB)* Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse deterrent fent-a-nyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on 5 potential breakout catalysts, NTRB needs full focus right now. Check them out: No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice No. 2 - Analyst From Zacks SCR Provides Massive $10 Target No. 3 - With A Potential Patent Issuance Nearing, NTRB Looks To Further Protect IP No. 4 - Announcement Of Revenue Up 46% Signals NTRB's Growth Potential No. 5 - Triggered Technicals Starting To Pop Up Across Short, Medium, And Long Term But more on those in a second... Nutriband's Lead Product - AVERSA™ The technology is based on the incorporation of taste and sensory aversive agents into the patch. The aversive agents are formulated in a controlled release matrix that is coated onto the back of a transdermal fent-a-nyl patch. The controlled release aspect of the technology is designed so that the abuse deterrent properties are maintained after normal use and during attempts to separate the aversive agents from the fent-a-nyl. Nutriband believes that this structure provides maximum exposure during oral abuse and during attempts to extract the drug, while preventing exposure of the patient to the aversive agents during transdermal wear. The company believes that a key differentiating aspect of the technology is that the aversive agents are physically separated from the drug matrix, meaning that the aversive agents do not have to be formulated in the fent-a-nyl drug matrix and do not contact the skin. In addition to the fent-a-nyl patch, they believe this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. - AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids - Nutriband's lead product is the AVERSA™ abuse deterrent fent-a-nyl transdermal system - Upon approval of AVERSA™ fent-a-nyl, we expect that FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics - Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$500Mn in revenue. AVERSA Pipeline [Grab Sources And More Key Details Here.]( ----- And as I mentioned above, NTRB has 5 key potential catalysts to soak in now. Here they are: No. 1 NTRB Potential Catalyst - Low Float Volatility Could Take Hold At A Moment's Notice According to the [Yahoo Finance]( website, NTRB has a low float. The website reports this profile to have approximately 4.7Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news early this year help provide a near term spark? ----- No. 2 NTRB Potential Catalyst - Analyst From Zacks SCR Provides Massive $10 Target Back in October of 2022, M. Marin, an analyst with [Zacks Small-Cap Research]( provided NTRB with a $10.00 target. From Wednesday's closing valuation, that provides NTRB with over 100+% potential upside. Here's some key highlights from the report: VALUATION Given NTRB’s steps to expand its operating footprint and protect its IP, we are optimistic about AVERSA’s commercial prospects, as the potential range of applicable uses for the AVERSA technology, the rising incidences of overdose deaths and high related healthcare costs could translate, we believe, into high demand for AVERSA following clinical studies. We are encouraged by the estimates from Health Advances. We believe in success NTRB could attain annual revenue in the $10Mn to $15Mn range by 2025-26 on its way to achieving scale and peak sales, depending on the commercialization timeline. We believe these forecasts are supported by the growing size of the target markets and AVERSA’s expected ability to improve the safety profile of fent-a-nyl and other prescription medications. Moreover, we also believe that competitive pressure could lead to adoption of the AVERSA technology by several large pharma companies in a short period, if the technology proves as efficient as NTRB believes it will. In fact, fent-a-nyl transdermal patches have become such an important pain therapy that they have been added to the WHO list of essential medicines, as noted, which we believe supports the positive outlook for AVERSA if clinical test results support its efficacy and safety. If the company can maintain its expected timeline and commercialize AVERSA by late 2024, our forecast could prove conservative, depending on several factors. It is difficult to compare NTRB to other more mature companies, in our view, given the early stage of development of AVERSA and the product portfolio. We would also expect NTRB to have a higher growth rate in the early years. Various other companies that are engaged in introducing new therapies and solutions and are at a similar stage of development have a wide range of price-to revenue multiples on forward estimates. Nevertheless, we believe the average price-to-sales multiple of companies in this comparison of about 14x provides a valuation benchmark for NTRB. Therefore, applying a 14x multiple to our above-noted forecast revenue range and discounting back to the present at 10%/year results in a present value of about $10 to $15 per share on a fully diluted basis, if the company initiates a successful launch of AVERSA. We expect the shares to begin to reflect the low end of this range as it hits certain milestones and incorporate the mid- to high-end as AVERSA development proceeds. Our forecast could change if and when the company expands the number of products leveraging the AVERSA technology. While there are several risks to the timeline and commercial launch, we think the current share price does not reflect the fundamental value of the company’s pipeline and prospects and would anticipate multiple expansion as the company continues to advance AVERSA. Any delay or failure in clinical development or regulatory approval could cause the share price to decline and represent a potential risk to our valuation but we believe the risk / reward ratio could be attractive for in-vest-ors who have a higher than average risk tolerance and longer time horizon. ----- No. 3 NTRB Potential Catalyst - With A Potential Patent Issuance Nearing, NTRB Looks To Further Protect IP Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on June 15, 2023 for patent application 17/568,999, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology. The receipt of a Notice of Allowance means that the USPTO is expected to issue a U.S. patent for this application after administrative processes have been completed. The expected issuance of this patent further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's lead product under development is Aversa™ FEN, an abuse deterrent FEN transdermal system, with the potential to become the first abuse deterrent pain patch on the market. [Read the full article here.]( ----- No. 4 NTRB Potential Catalyst - Announcement Of Revenue Up 46% Signals NTRB's Growth Potential Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023 ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced fin-a-ncial and operational results for the fiscal year ended January 31, 2023. Key Highlights: - Generated record revenue of $2.1Mn, up 46% over the prior fiscal year - Successfully obtained court verdict for recovery of shares constituting 15% of its total outstanding shares - Announced a Seven-for-Six Forward st-ock split to reward shareholders following the successful court verdict - Received notice of allowance from the Canadian Intellectual Property Office for AVERSA™ patent completing patent issuance in all of North America - Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for AVERSA™ FEN ... - Company COO, Alan Smith Ph.D selected for FDA Centre for Research on Complex Generics Expert Committee - With Kindeva Drug Delivery, selected AVERSA™ FEN Abuse Deterrent Formulation for commercial scale manufacturing process development "Our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year. We have made significant progress with AVERSA™ and our goal to improve the safety profile of easily abused transdermal drugs. Our record fin-an-cial results and multiple major achievements in fiscal 2022 were a direct result of the hard work and exceptional execution of our dedicated team," commented Gareth Sheridan, CEO of Nutriband. "We look forward to continuing to positively update our shareholders as we have laid out major milestone targets for 2023 which we intend to achieve as in previous years.'' "According to an assessment by Health Advances, AVERSA™ FEN could reach peak annual sales of between $80Mn and $200Mn. If the entire transdermal FEN market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater," continued Sheridan. "I want to thank our shareholders for their ongoing support as we continue to execute on our vision of commercializing our innovative transdermal abuse deterrent technology, AVERSA™." ... [Read the full article here.]( ----- No. 5 NTRB Potential Catalyst - Triggered Technicals Starting To Pop Up Across Short, Medium, And Long Term Since last week, [Barchart]( has been reporting several technical indicators for NTRB to become triggered across the short, medium, and long term. Take a look at the list (at close Wednesday): - 20 Day Moving Average - 50 Day Moving Average - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator On top of those, Barchart's composite "Trend Seeker" indicator has also become triggered. Could these technicals cause NTRB to start popping up on radars everywhere this week? Keep an eye on these closely starting now. ----- NTRB Recap - 5 Key Potential Breakout Catalysts For This Nasdaq Idea No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice No. 2 - Analyst From Zacks SCR Provides Massive $10 Target No. 3 - With A Potential Patent Issuance Nearing, NTRB Looks To Further Protect IP No. 4 - Announcement Of Revenue Up 46% Signals NTRB's Growth Potential No. 5 - Triggered Technicals Starting To Pop Up Across Short, Medium, And Long Term ----- Coverage is officially initiated on NTRB. To ensure receiving all updates, do this: Get NTRB on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. We have previously profiled (NTRB) in 2023, but were not compensated for disseminating information via Website, Email and SMS. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 7/26/23 and ending on 7/27/23 to publicly disseminate information about (NTRB) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (NTRB). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 07/24/2023 and ending on 08/04/2023 to publicly disseminate information about (NTRB:US) via digital communications. We have been paid one hundred twenty five thousand dollars USD. We own zero shares of (NTRB:US). Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net